KLRA earnings date and last-quarter result: last quarter miss, P/E -14.12. Updated 2026-07-23.
Kailera Therapeutics (KLRA) Research Hub
Kailera Therapeutics (KLRA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 12.77 USD (-0.62%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.12, market cap 2.36B. This hub links to the full technical, earnings and options research available for KLRA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 12.77 USD (-0.62%) |
| 52-week range | 9.76 USD – 23.82 USD |
| Trend regime | Range |
| 14-day RSI | 63.4 (Bullish) |
| Trailing P/E | -14.12 |
| Market cap | 2.36B |
| Dividend yield | 0.00% |
Available research for KLRA
Covered Call on KLRA: how it works, illustrative setup around the real 12.77 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KLRA: how it works, illustrative setup around the real 12.77 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KLRA: how it works, illustrative setup around the real 12.77 USD price, max profit/loss, breakeven and when to use it. Educational.
KLRA technical analysis: range, last 12.77 USD, RSI 63.4, 52w range 9.76 USD–23.82 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is KLRA in?
Kailera Therapeutics (KLRA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KLRA in an uptrend or downtrend?
As of 2026-10-26, KLRA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KLRA's trailing P/E ratio?
KLRA's trailing P/E is -14.12, with a market cap of 2.36B. See the earnings research page for full valuation detail.